SCHEMBL241329

SCHEMBL241329

CCCN(C(=O)C(F)(F)F)[C@H]1C[C@@H](n2cnc3c(NCCc4ccc(S(N)(=O)=O)cc4)nc(N4CC[C@@H](N(C)C)C4)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 10/20 0.36
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
TMIGD3 P0DMS9 3/20 0.33
ADORA2A P29274 3/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ADORA1 P30542 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA2B P29275 1/20 0.32
CDK1 P06493 1/20 0.31
CDK5 Q00535 1/20 0.31
CA12 O43570 1/20 0.31
CA4 P22748 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA13 Q8N1Q1 1/20 0.31
CA14 Q9ULX7 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124600 0.93 CCNE2 (0.37) ADORA3CA1CA2CA9TMIGD3
SCHEMBL4119749 0.87 ADORA3 (0.34) ADORA3CA1CA2CA9TMIGD3
SCHEMBL241672 0.87 HRH4 (0.38) ADORA3ADORA2AHRH4HRH3ADORA1
SCHEMBL4110160 0.86 DNMT1 (0.39) ADORA3CA1CA2CA9ADORA2A
SCHEMBL244140 0.85 ADORA2A (0.38) ADORA3ADORA2AHRH4HRH3CDK1
Trifluoroacetic Acid SCHEMBL241327 0.85 ADORA2A (0.43) ADORA3ADORA2AHRH4HRH3
SCHEMBL244161 0.83 CDK1 (0.36) ADORA3ADORA2AHRH4HRH3CDK1
SCHEMBL244571 0.83 ADORA2A (0.42) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL243067 0.83 ADORA2A (0.38) ADORA3TMIGD3ADORA2AHRH4HRH3
SCHEMBL242701 0.82 HRH4 (0.34) ADORA3ADORA2AHRH4HRH3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318750-B2 Organic compounds NOVARTIS AG (NL) 2012-11-27 US disclosed
US-8258141-B2 Organic compounds NOVARTIS AG (CH) 2012-09-04 US disclosed
EP-2013211-B1 PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2012-03-14 EP disclosed
US-20120004212-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20120004247-A1 ORGANIC COMPOUNDS NOVARTIS AG 2012-01-05 US disclosed
US-20100286126-A1 Organic Compounds NOVARTIS AG (CH) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286126-A1 Organic Compounds CYP3A43, SLCO1B3, CYP2C19 ADORA3 795/4885CA1 3204/4885CA2 2138/4885
US-20120004212-A1 ORGANIC COMPOUNDS CYP3A43, SLCO1B3, CYP2C19 ADORA3 795/4885CA1 3204/4885CA2 2138/4885
US-20120004247-A1 ORGANIC COMPOUNDS CYP3A43, SLCO1B3, CYP2C19 ADORA3 795/4885CA1 3204/4885CA2 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.